Scaling At-home Infectious Disease Diagnostics: From Promise to Practice
The COVID-19 pandemic catalyzed the decentralization of diagnostics, bringing them into homes from lab floors. With the FDA approving at-home testing kits for STIs and respiratory infections, the infectious disease diagnostics market is embracing its watershed moment. It is slated to reach $46.05 billion by 2032 at an implied CAGR of 7.89%. Currently, at-home diagnostic […]
Opportunity Mapping – At-home Diagnostics
A leading diagnostics company sought to expand into the at-home testing segment, targeting aging populations (55+ years) in the US, EU, and Japan, focusing on cardiovascular, kidney, and metabolic health.While the company already had point-of-care and lab-based biomarker solutions, leadership sought to evaluate whether a combined at-home panel could be a commercially viable and clinically […]
Decentralization Dilemma – Why Diagnostic OEMs Must Redefine Relevance?
HPV Self-Sampling & Diagnostic Decentralization Business Hypothesis: As self-sampling and decentralized screening become mainstream, diagnostic value will migrate from centralized assay throughput to distributed patient participation. Traditional OEM business models, which rely on reagent volume, lab automation, and service lock-ins, continue to face the risk of economic erosion unless they redefine how and where they […]